ASH News Daily 2017 - Issue 3 - C-30
ASH News Daily
Page C-30
Monday, December 11, 2017
®
Monday's Poster Sessions
Session ...................................................... Paper Ranges
401. Basic Science and Clinical Practice in Blood Transfusion: Poster III ......... 3726 - 3745
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular
Markers in Diagnosis and Prognosis: Poster III.......................................... 3904 - 3969
618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and
Molecular Markers in Diagnosis and Prognosis: Poster III ......................... 3970 - 3993
621. Lymphoma-Genetic/Epigenetic Biology: Poster III ................................... 3994 - 4016
622. Lymphoma Biology-Non-Genetic Studies: Poster III ................................ 4017 - 4035
623. Mantle Cell, Follicular, and Other Indolent B-Cell
Lymphoma-Clinical Studies: Poster III ..................................................... 4036 - 4069
624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster III .....4070 - 4099
625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents: Poster III ..... 4100 - 4114
626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive
B-Cell Non-Hodgkin Lymphomas)-Results from Prospective
Clinical Trials: Poster III .............................................................................. 4115 - 4129
627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive
B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/
Observational Studies: Poster III ................................................................ 4130 - 4169
631. Chronic Myeloid Leukemia: Biology and Pathophysiology,
excluding Therapy: Poster III ...................................................................... 4170 - 4178
634. Myeloproliferative Syndromes: Clinical: Poster III ...................................... 4179 - 4208
635. Myeloproliferative Syndromes: Basic Science: Poster III ........................... 4209 - 4226
636. Myelodysplastic Syndromes-Basic and Translational Studies: Poster III ....4227 - 4245
637. Myelodysplastic Syndromes-Clinical Studies: Poster III .......................... 4246 - 4277
641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III ............. 4278 - 4306
642. CLL: Therapy, excluding Transplantation: Poster III ................................... 4307 - 4330
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III ..... 4331 - 4408
652. Myeloma: Pathophysiology and Pre-Clinical Studies,
excluding Therapy: Poster III ...................................................................... 4409 - 4430
500s
700s
501. Hematopoietic Stem and Progenitor Biology: Poster III ............................. 3746 - 3763
502. Hematopoiesis: Regulation of Gene Transcription, Cytokines,
Signal Transduction, Apoptosis, and Cell Cycle Regulation: Poster III....... 3764 - 3774
506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion,
and Stromal Stem Cells: Poster III ............................................................. 3775 - 3784
701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster III .....4431 - 4449
703. Adoptive Immunotherapy: Poster III ........................................................... 4450 - 4468
711. Cell Collection and Processing: Poster III................................................... 4469 - 4478
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD,
Immune Reconstitution: Poster III .............................................................. 4479 - 4508
723. Clinical Allogeneic and Autologous Transplantation: Late
Complications and Approaches to Disease Recurrence: Poster III ............ 4509 - 4531
731. Clinical Autologous Transplantation: Results: Poster III ............................. 4532 - 4553
732. Clinical Allogeneic Transplantation: Results: Poster III............................... 4554 - 4608
100s
101. Red Cells and Erythropoiesis, Structure and Function,
Metabolism, and Survival, Excluding Iron: Poster III .................................. 3467 - 3491
102. Regulation of Iron Metabolism: Poster III ................................................... 3492 - 3500
112. Thalassemia and Globin Gene Regulation: Poster III ................................. 3501 - 3509
113. Hemoglobinopathies, Excluding Thalassemia-Basic and
Translational Science: Poster III ................................................................. 3510 - 3527
114. Hemoglobinopathies, Excluding Thalassemia-Clinical: Poster III............. 3528 - 3559
200s
201. Granulocytes, Monocytes, and Macrophages: Poster III ............................ 3560 - 3575
203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency,
including HIV and Other Infections: Poster III............................................. 3576 - 3598
300s
301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet
Adhesion, Activation, and Biochemistry: Poster III ..................................... 3599 - 3614
311. Disorders of Platelet Number or Function: Poster III .................................. 3615 - 3648
321. Blood Coagulation and Fibrinolytic Factors: Poster III................................ 3649 - 3664
322. Disorders of Coagulation or Fibrinolysis: Poster III .................................... 3665 - 3693
331. Pathophysiology of Thrombosis: Poster III ................................................. 3694 - 3710
332. Antithrombotic Therapy: Poster III .............................................................. 3711 - 3725
400s
600s
602. Disordered Gene Expression in Hematologic Malignancy, including
Disordered Epigenetic Regulation: Poster III.............................................. 3785 - 3812
604. Molecular Pharmacology and Drug Resistance in Myeloid
Diseases: Poster III .................................................................................... 3813 - 3833
605. Molecular Pharmacology, Drug Resistance-Lymphoid and Other
Diseases: Poster III .................................................................................... 3834 - 3848
613. Acute Myeloid Leukemia: Clinical Studies: Poster III.................................. 3849 - 3875
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation:
Poster III ..................................................................................................... 3876 - 3894
615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding
Transplantation: Poster III........................................................................... 3895 - 3903
800s
801. Gene Therapy and Transfer: Poster III ....................................................... 4609 - 4621
802. Chemical Biology and Experimental Therapeutics: Poster III..................... 4622 - 4630
900s
901. Health Services Research-Non-Malignant Conditions: Poster III............. 4631 - 4669
902. Health Services Research-Malignant Conditions: Poster III .................... 4670 - 4717
903. Outcomes Research-Non-Malignant Conditions: Poster III ..................... 4718 - 4737
Posters will be available for
viewing in Hall A2 of the
Georgia World Congress Center
at the times listed below.
Meeting attendees will have the
opportunity to meet the
abstract authors to discuss their
research and ask questions
during the presentation times
listed. Attendees can also take
advantage of PosterCast, a new
feature that provides audio
narration of posters, recorded
directly by the author. Visit the
poster hall to learn more.
Monday, December 11
Poster Session III - Viewing:
10:00 a.m. - 8:00 p.m.
Poster Session III - Presentations:
6:00 p.m. - 8:00 p.m.
Poster Hall Reception:
6:00 p.m. - 8:00 p.m.
Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 3
ASH News Daily 2017 - Issue 3 - A-1
ASH News Daily 2017 - Issue 3 - A-2
ASH News Daily 2017 - Issue 3 - A-3
ASH News Daily 2017 - Issue 3 - A-4
ASH News Daily 2017 - Issue 3 - A-5
ASH News Daily 2017 - Issue 3 - A-6
ASH News Daily 2017 - Issue 3 - A-7
ASH News Daily 2017 - Issue 3 - A-8
ASH News Daily 2017 - Issue 3 - A-9
ASH News Daily 2017 - Issue 3 - A-10
ASH News Daily 2017 - Issue 3 - A-11
ASH News Daily 2017 - Issue 3 - A-12
ASH News Daily 2017 - Issue 3 - A-13
ASH News Daily 2017 - Issue 3 - A-14
ASH News Daily 2017 - Issue 3 - A-15
ASH News Daily 2017 - Issue 3 - A-16
ASH News Daily 2017 - Issue 3 - A-17
ASH News Daily 2017 - Issue 3 - A-18
ASH News Daily 2017 - Issue 3 - A-19
ASH News Daily 2017 - Issue 3 - A-20
ASH News Daily 2017 - Issue 3 - A-21
ASH News Daily 2017 - Issue 3 - A-22
ASH News Daily 2017 - Issue 3 - A-23
ASH News Daily 2017 - Issue 3 - A-24
ASH News Daily 2017 - Issue 3 - A-25
ASH News Daily 2017 - Issue 3 - A-26
ASH News Daily 2017 - Issue 3 - A-27
ASH News Daily 2017 - Issue 3 - A-28
ASH News Daily 2017 - Issue 3 - B-1
ASH News Daily 2017 - Issue 3 - B-2
ASH News Daily 2017 - Issue 3 - B-3
ASH News Daily 2017 - Issue 3 - B-4
ASH News Daily 2017 - Issue 3 - B-5
ASH News Daily 2017 - Issue 3 - B-6
ASH News Daily 2017 - Issue 3 - B-7
ASH News Daily 2017 - Issue 3 - B-8
ASH News Daily 2017 - Issue 3 - B-9
ASH News Daily 2017 - Issue 3 - B-10
ASH News Daily 2017 - Issue 3 - B-11
ASH News Daily 2017 - Issue 3 - B-12
ASH News Daily 2017 - Issue 3 - B-13
ASH News Daily 2017 - Issue 3 - B-14
ASH News Daily 2017 - Issue 3 - B-15
ASH News Daily 2017 - Issue 3 - B-16
ASH News Daily 2017 - Issue 3 - B-17
ASH News Daily 2017 - Issue 3 - B-18
ASH News Daily 2017 - Issue 3 - B-19
ASH News Daily 2017 - Issue 3 - B-20
ASH News Daily 2017 - Issue 3 - B-21
ASH News Daily 2017 - Issue 3 - B-22
ASH News Daily 2017 - Issue 3 - B-23
ASH News Daily 2017 - Issue 3 - B-24
ASH News Daily 2017 - Issue 3 - B-25
ASH News Daily 2017 - Issue 3 - B-26
ASH News Daily 2017 - Issue 3 - B-27
ASH News Daily 2017 - Issue 3 - B-30
ASH News Daily 2017 - Issue 3 - B-31
ASH News Daily 2017 - Issue 3 - B-32
ASH News Daily 2017 - Issue 3 - B-33
ASH News Daily 2017 - Issue 3 - B-34
ASH News Daily 2017 - Issue 3 - B-35
ASH News Daily 2017 - Issue 3 - B-36
ASH News Daily 2017 - Issue 3 - B-37
ASH News Daily 2017 - Issue 3 - B-38
ASH News Daily 2017 - Issue 3 - B-39
ASH News Daily 2017 - Issue 3 - B-40
ASH News Daily 2017 - Issue 3 - B-41
ASH News Daily 2017 - Issue 3 - B-42
ASH News Daily 2017 - Issue 3 - B-43
ASH News Daily 2017 - Issue 3 - B-44
ASH News Daily 2017 - Issue 3 - B-45
ASH News Daily 2017 - Issue 3 - B-46
ASH News Daily 2017 - Issue 3 - B-47
ASH News Daily 2017 - Issue 3 - B-48
ASH News Daily 2017 - Issue 3 - B-49
ASH News Daily 2017 - Issue 3 - B-50
ASH News Daily 2017 - Issue 3 - B-51
ASH News Daily 2017 - Issue 3 - B-52
ASH News Daily 2017 - Issue 3 - B-53
ASH News Daily 2017 - Issue 3 - B-54
ASH News Daily 2017 - Issue 3 - B-55
ASH News Daily 2017 - Issue 3 - B-56
ASH News Daily 2017 - Issue 3 - C-1
ASH News Daily 2017 - Issue 3 - C-2
ASH News Daily 2017 - Issue 3 - C-3
ASH News Daily 2017 - Issue 3 - C-4
ASH News Daily 2017 - Issue 3 - C-5
ASH News Daily 2017 - Issue 3 - C-6
ASH News Daily 2017 - Issue 3 - C-7
ASH News Daily 2017 - Issue 3 - C-8
ASH News Daily 2017 - Issue 3 - C-9
ASH News Daily 2017 - Issue 3 - C-10
ASH News Daily 2017 - Issue 3 - C-11
ASH News Daily 2017 - Issue 3 - C-12
ASH News Daily 2017 - Issue 3 - C-13
ASH News Daily 2017 - Issue 3 - C-14
ASH News Daily 2017 - Issue 3 - C-15
ASH News Daily 2017 - Issue 3 - C-16
ASH News Daily 2017 - Issue 3 - C-17
ASH News Daily 2017 - Issue 3 - C-18
ASH News Daily 2017 - Issue 3 - C-19
ASH News Daily 2017 - Issue 3 - C-20
ASH News Daily 2017 - Issue 3 - C-21
ASH News Daily 2017 - Issue 3 - C-22
ASH News Daily 2017 - Issue 3 - C-23
ASH News Daily 2017 - Issue 3 - C-24
ASH News Daily 2017 - Issue 3 - C-25
ASH News Daily 2017 - Issue 3 - C-26
ASH News Daily 2017 - Issue 3 - C-27
ASH News Daily 2017 - Issue 3 - C-28
ASH News Daily 2017 - Issue 3 - C-29
ASH News Daily 2017 - Issue 3 - C-30
ASH News Daily 2017 - Issue 3 - C-31
ASH News Daily 2017 - Issue 3 - C-32
https://www.nxtbookmedia.com